Regeneration of dopaminergic neurons after 6-hydroxydopamine-induced lesion in planarian brain. 2011

Kaneyasu Nishimura, and Takeshi Inoue, and Kanji Yoshimoto, and Takashi Taniguchi, and Yoshihisa Kitamura, and Kiyokazu Agata
Department of Biophysics, Graduate School of Science, Kyoto University, Oiwake, Kitashirakawa, Sakyo-ku, Kyoto, Japan.

Planarians have robust regenerative ability dependent on X-ray-sensitive pluripotent stem cells, called neoblasts. Here, we report that planarians can regenerate dopaminergic neurons after selective degeneration of these neurons caused by treatment with a dopaminergic neurotoxin (6-hydroxydopamine; 6-OHDA). This suggests that planarians have a system to sense the degeneration of dopaminergic neurons and to recruit stem cells to produce dopaminergic neurons to recover brain morphology and function. We confirmed that X-ray-irradiated planarians do not regenerate brain dopaminergic neurons after 6-OHDA-induced lesioning, suggesting that newly generated dopaminergic neurons are indeed derived from pluripotent stem cells. However, we found that the majority of regenerated dopaminergic neurons were 5-bromo-2'-deoxyuridine-negative cells. Therefore, we carefully analyzed when proliferating stem cells became committed to become dopaminergic neurons during regeneration by a combination of 5-bromo-2'-deoxyuridine pulse-chase experiments, immunostaining/in situ hybridization, and 5-fluorouracil treatment. The results strongly suggested that G(2) -phase stem cells become committed to dopaminergic neurons in the mesenchymal space around the brain, after migration from the trunk region following S-phase. These new findings obtained from planarian regeneration provide hints about how to conduct cell-transplantation therapy for future regenerative medicine.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D009416 Nerve Regeneration Renewal or physiological repair of damaged nerve tissue. Nerve Tissue Regeneration,Nervous Tissue Regeneration,Neural Tissue Regeneration,Nerve Tissue Regenerations,Nervous Tissue Regenerations,Neural Tissue Regenerations,Regeneration, Nerve,Regeneration, Nerve Tissue,Regeneration, Nervous Tissue,Regeneration, Neural Tissue,Tissue Regeneration, Nerve,Tissue Regeneration, Nervous,Tissue Regeneration, Neural
D009498 Neurotoxins Toxic substances from microorganisms, plants or animals that interfere with the functions of the nervous system. Most venoms contain neurotoxic substances. Myotoxins are included in this concept. Alpha-Neurotoxin,Excitatory Neurotoxin,Excitotoxins,Myotoxin,Myotoxins,Neurotoxin,Alpha-Neurotoxins,Excitatory Neurotoxins,Excitotoxin,Alpha Neurotoxin,Alpha Neurotoxins,Neurotoxin, Excitatory,Neurotoxins, Excitatory
D010932 Planarians Nonparasitic free-living flatworms of the class Turbellaria. The most common genera are Dugesia, formerly Planaria, which lives in water, and Bipalium, which lives on land. Geoplana occurs in South America and California. Dugesia,Dugesias,Planarian
D001930 Brain Injuries Acute and chronic (see also BRAIN INJURIES, CHRONIC) injuries to the brain, including the cerebral hemispheres, CEREBELLUM, and BRAIN STEM. Clinical manifestations depend on the nature of injury. Diffuse trauma to the brain is frequently associated with DIFFUSE AXONAL INJURY or COMA, POST-TRAUMATIC. Localized injuries may be associated with NEUROBEHAVIORAL MANIFESTATIONS; HEMIPARESIS, or other focal neurologic deficits. Brain Lacerations,Acute Brain Injuries,Brain Injuries, Acute,Brain Injuries, Focal,Focal Brain Injuries,Injuries, Acute Brain,Injuries, Brain,Acute Brain Injury,Brain Injury,Brain Injury, Acute,Brain Injury, Focal,Brain Laceration,Focal Brain Injury,Injuries, Focal Brain,Injury, Acute Brain,Injury, Brain,Injury, Focal Brain,Laceration, Brain,Lacerations, Brain
D001973 Bromodeoxyuridine A nucleoside that substitutes for thymidine in DNA and thus acts as an antimetabolite. It causes breaks in chromosomes and has been proposed as an antiviral and antineoplastic agent. It has been given orphan drug status for use in the treatment of primary brain tumors. BUdR,BrdU,Bromouracil Deoxyriboside,Broxuridine,5-Bromo-2'-deoxyuridine,5-Bromodeoxyuridine,NSC-38297,5 Bromo 2' deoxyuridine,5 Bromodeoxyuridine,Deoxyriboside, Bromouracil
D002453 Cell Cycle The complex series of phenomena, occurring between the end of one CELL DIVISION and the end of the next, by which cellular material is duplicated and then divided between two daughter cells. The cell cycle includes INTERPHASE, which includes G0 PHASE; G1 PHASE; S PHASE; and G2 PHASE, and CELL DIVISION PHASE. Cell Division Cycle,Cell Cycles,Cell Division Cycles,Cycle, Cell,Cycle, Cell Division,Cycles, Cell,Cycles, Cell Division,Division Cycle, Cell,Division Cycles, Cell
D002465 Cell Movement The movement of cells from one location to another. Distinguish from CYTOKINESIS which is the process of dividing the CYTOPLASM of a cell. Cell Migration,Locomotion, Cell,Migration, Cell,Motility, Cell,Movement, Cell,Cell Locomotion,Cell Motility,Cell Movements,Movements, Cell
D002795 Choline O-Acetyltransferase An enzyme that catalyzes the formation of acetylcholine from acetyl-CoA and choline. EC 2.3.1.6. Choline Acetylase,Choline Acetyltransferase,Acetylase, Choline,Acetyltransferase, Choline,Choline O Acetyltransferase,O-Acetyltransferase, Choline
D002851 Chromatography, High Pressure Liquid Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed. Chromatography, High Performance Liquid,Chromatography, High Speed Liquid,Chromatography, Liquid, High Pressure,HPLC,High Performance Liquid Chromatography,High-Performance Liquid Chromatography,UPLC,Ultra Performance Liquid Chromatography,Chromatography, High-Performance Liquid,High-Performance Liquid Chromatographies,Liquid Chromatography, High-Performance

Related Publications

Kaneyasu Nishimura, and Takeshi Inoue, and Kanji Yoshimoto, and Takashi Taniguchi, and Yoshihisa Kitamura, and Kiyokazu Agata
September 2016, Anais da Academia Brasileira de Ciencias,
Kaneyasu Nishimura, and Takeshi Inoue, and Kanji Yoshimoto, and Takashi Taniguchi, and Yoshihisa Kitamura, and Kiyokazu Agata
September 1996, Brain research,
Kaneyasu Nishimura, and Takeshi Inoue, and Kanji Yoshimoto, and Takashi Taniguchi, and Yoshihisa Kitamura, and Kiyokazu Agata
November 2000, The Journal of comparative neurology,
Kaneyasu Nishimura, and Takeshi Inoue, and Kanji Yoshimoto, and Takashi Taniguchi, and Yoshihisa Kitamura, and Kiyokazu Agata
February 1996, Neuroscience letters,
Kaneyasu Nishimura, and Takeshi Inoue, and Kanji Yoshimoto, and Takashi Taniguchi, and Yoshihisa Kitamura, and Kiyokazu Agata
January 1988, Experimental brain research,
Kaneyasu Nishimura, and Takeshi Inoue, and Kanji Yoshimoto, and Takashi Taniguchi, and Yoshihisa Kitamura, and Kiyokazu Agata
August 2012, Archiv der Pharmazie,
Kaneyasu Nishimura, and Takeshi Inoue, and Kanji Yoshimoto, and Takashi Taniguchi, and Yoshihisa Kitamura, and Kiyokazu Agata
May 2004, Journal of neuroscience research,
Kaneyasu Nishimura, and Takeshi Inoue, and Kanji Yoshimoto, and Takashi Taniguchi, and Yoshihisa Kitamura, and Kiyokazu Agata
September 2008, Neuroscience,
Kaneyasu Nishimura, and Takeshi Inoue, and Kanji Yoshimoto, and Takashi Taniguchi, and Yoshihisa Kitamura, and Kiyokazu Agata
June 1998, Journal of molecular neuroscience : MN,
Kaneyasu Nishimura, and Takeshi Inoue, and Kanji Yoshimoto, and Takashi Taniguchi, and Yoshihisa Kitamura, and Kiyokazu Agata
September 1993, Neuroscience letters,
Copied contents to your clipboard!